切换至 "中华医学电子期刊资源库"

中华普通外科学文献(电子版) ›› 2024, Vol. 18 ›› Issue (02) : 142 -146. doi: 10.3877/cma.j.issn.1674-0793.2024.02.015

综述

微小RNAs 在胆管癌发生发展和诊治中的作用
郑敏超1,2, 李成功1,2, 陈志强1,2, 商中华1,()   
  1. 1. 030000 太原,山西医科大学第二医院普通外科
    2. 030000 太原,山西医科大学
  • 收稿日期:2023-07-12 出版日期:2024-04-01
  • 通信作者: 商中华

Roles of microRNAs in the development, diagnosis and treatment of cholangiocarcinoma

Minchao Zheng1,2, Chenggong Li1,2, Zhiqiang Chen1,2, Zhonghua Shang1,()   

  1. 1. Department of General Surgery, the Second Hospital of Shanxi Medical University, Taiyuan 030000, China
    2. Shanxi Medical University, Taiyuan 030000, China
  • Received:2023-07-12 Published:2024-04-01
  • Corresponding author: Zhonghua Shang
引用本文:

郑敏超, 李成功, 陈志强, 商中华. 微小RNAs 在胆管癌发生发展和诊治中的作用[J/OL]. 中华普通外科学文献(电子版), 2024, 18(02): 142-146.

Minchao Zheng, Chenggong Li, Zhiqiang Chen, Zhonghua Shang. Roles of microRNAs in the development, diagnosis and treatment of cholangiocarcinoma[J/OL]. Chinese Archives of General Surgery(Electronic Edition), 2024, 18(02): 142-146.

胆管癌是一种起源于胆道上皮的恶性肿瘤,其发病率低但致死率高,患者被确诊时大多已处于晚期阶段,即使进行及时有效的外科手术干预,其预后效果仍然不尽人意。这就要求临床医师可以早期发现、诊断,进而早期采取措施进行治疗。本综述旨在概述微小RNAs(miRNAs)在胆管癌发生、发展和诊治中的作用,为临床工作提供参考意义。

Cholangiocarcinoma is a malignant tumor originating from biliary epithelium, so that its incidence rate is relatively low, but the fatality rate is high.Most patients are at late stage when they are diagnosed.Even with timely and effective surgical intervention at the time, the prognosis is still unsatisfactory.Early detection, diagnosis, and treatment is essential.This review aims to summarize the role of microRNAs (miRNAs) in the development, diagnosis and treatment of cholangiocarcinoma and provide references for clinical work.

[1]
Sun C, Zhu J, Wu B, et al.Diagnostic and prognostic value of microRNAs in cholangiocarcinoma: A systematic review and metaanalysis[J].Cancer Manag Res, 2018, 10: 2125-2139.
[2]
Shi T, Morishita A, Kobara H, et al.The role of microRNAs in cholangiocarcinoma[J].Int J Mol Sci, 2021, 22(14): 7627.
[3]
Inoue J, Inazawa J.Cancer-associated miRNAs and their therapeutic potential[J].J Hum Genet, 2021, 66(9): 937-945.
[4]
Bhootra S, Jill N, Shanmugam G, et al.DNA methylation and cancer: transcriptional regulation, prognostic, and therapeutic perspective[J].Med Oncol, 2023, 40(2): 71.
[5]
Chen YJ, Luo J, Yang GY, et al.Mutual regulation between microRNA-373 and methyl-CpG-binding domain protein 2 in hilar cholangiocarcinoma[J].World J Gastroenterol, 2012, 18(29):3849-3861.
[6]
Shah JA, Khattak S, Rauf MA, et al.Potential biomarkers of miR-371-373 gene cluster in tumorigenesis[J].Life (Basel), 2021,11(9): 984.
[7]
Li H, Zhou ZQ, Yang ZR, et al.microRNA-191 acts as a tumor promoter by modulating the TET1-p53 pathway in intrahepatic cholangiocarcinoma[J].Hepatology, 2017, 66(1): 136-151.
[8]
Ursu S, Majid S, Garger C, et al.Novel tumor suppressor role of miRNA-876 in cholangiocarcinoma[J].Oncogenesis, 2019, 8(8):42.
[9]
Sarcognato S, Gringeri E, Fassan M, et al.Prognostic role of BAP-1 and PBRM-1 expression in intrahepatic cholangiocarcinoma[J].Virchows Arch, 2019, 474(1): 29-37.
[10]
Wang LJ, He CC, Sui X, et al.miR-21 promotes intrahepatic cholangiocarcinoma proliferation and growth in vitro and in vivo by targeting PTPN14 and PTEN[J].Oncotarget, 2015, 6(8): 5932-5946.
[11]
Liu CH, Huang Q, Jin ZY, et al.miR-21 and KLF4 jointly augment epithelial-mesenchymal transition via the Akt/ERK1/2 pathway[J].Int J Oncol, 2017, 50(4): 1109-1115.
[12]
Zhang JW, Wang X, Li GC, et al.miR-30a-5p promotes cholangiocarcinoma cell proliferation through targeting SOCS3[J].J Cancer, 2020, 11(12): 3604-3614.
[13]
Hu ZG, Zheng CW, Su HZ, et al.microRNA-329-mediated PTTG1 downregulation inactivates the MAPK signaling pathway to suppress cell proliferation and tumor growth in cholangiocarcinoma[J].J Cell Biochem, 2019, 120(6): 9964-9978.
[14]
Liao CH, Liu Y, Wu YF, et al.microRNA-329 suppresses epithelial-to-mesenchymal transition and lymph node metastasis in bile duct cancer by inhibiting laminin subunit beta 3[J].J Cell Physiol, 2019, 234(10): 17786-17799.
[15]
Fu W, Yu G, Liang J, et al.miR-144-5p and miR-451a inhibit the growth of cholangiocarcinoma cells through decreasing the expression of ST8SIA4[J].Front Oncol, 2020, 10: 563486.
[16]
Chen C, Jiang J, Fang M, et al.microRNA-129-2-3p directly targets Wip1 to suppress the proliferation and invasion of intrahepatic cholangiocarcinoma[J].J Cancer, 2020, 11(11): 3216-3224.
[17]
Ma J, Weng L, Wang Z, et al.miR-124 induces autophagy-related cell death in cholangiocarcinoma cells through direct targeting of the EZH2-STAT3 signaling axis[J].Exp Cell Res, 2018, 366(2):103-113.
[18]
Xu Z, Liu G, Zhang M, et al.miR-122-5p inhibits the proliferation, invasion and growth of bile duct carcinoma cells by targeting ALDOA[J].Cell Physiol Biochem, 2018, 48(6): 2596-2606.
[19]
Chang W, Wang Y, Li W, et al.microRNA-551b-3p inhibits tumour growth of human cholangiocarcinoma by targeting cyclin D1[J].J Cell Mol Med, 2019, 23(8): 4945-4954.
[20]
Cao K, Sun L, Zhang Y, et al.Overpression of miR-29b suppresses the proliferation and induces apoptosis of cholangiocarcinoma cells[J].Nan Fang Yi Ke Da Xue Xue Bao, 2018, 38(10): 1234-1238.
[21]
Cao K, Li B, Zhang YW, et al.miR-29b restrains cholangiocarcinoma progression by relieving DNMT3B-mediated repression of CDKN2B expression[J].Aging (Albany NY), 2021, 13(4): 6055-6065.
[22]
Liu B, Hu Y, Qin L, et al.microRNA-494-dependent WDHDI inhibition suppresses epithelial-mesenchymal transition, tumor growth and metastasis in cholangiocarcinoma[J].Dig Liver Dis,2019, 51(3): 397-411.
[23]
Gao J, Dai C, Yu X, et al.Upregulated microRNA-194 impairs stemness of cholangiocarcinoma cells through the Rho pathway via inhibition of ECT2[J].J Cell Biochem, 2020, 121(10): 4239-4250.
[24]
Loosen SH, Lurje G, Wiltberger G, et al.Serum levels of miR-29,miR-122, miR-155 and miR-192 are elevated in patients with cholangiocarcinoma[J].PLoS One, 2019, 14(1): e0210944.
[25]
Han HS, Kim MJ, Han JH, et al.Bile-derived circulating extracellular miR-30d-5p and miR-92a-3p as potential biomarkers for cholangiocarcinoma[J].Hepatobiliary Pancreat Dis Int, 2020, 19(1): 41-50.
[26]
Salem P, Ghazala RA, El Gendi AM, et al.The association between circulating microRNA-150 level and cholangiocarcinoma[J].J Clin Lab Anal, 2020, 34(11): e23397.
[27]
Gao L, Yang X, Zhang H, et al.Inhibition of miR-10a-5p suppresses cholangiocarcinoma cell growth through downregulation of Akt pathway[J].Onco Targets Ther, 2018, 11: 6981-6994.
[28]
Cheng Q, Feng F, Zhu L, et al.Circulating miR-106a is a novel prognostic and lymph node metastasis indicator for cholangiocarcinoma[J].Sci Rep, 2015, 5: 16103.
[29]
Zhou Z, Ma J.miR-378 serves as a prognostic biomarker in cholangiocarcinoma and promotes tumor proliferation, migration,and invasion[J].Cancer Biomark, 2019, 24(2): 173-181.
[30]
乌吉斯古楞, 哈斯高娃.mir-98-5p、ALKBH1 在肝门部胆管癌组织中表达及与临床病理特征的关系[J/OL].中华普外科手术学杂志(电子版), 2024, 18(2): 184-187.
[31]
Yao Y, Jiao D, Liu Z, et al.Novel miRNA predicts survival and prognosis of cholangiocarcinoma based on RNA-seq data and in vitro experiments[J].Biomed Res Int, 2020, 2020: 5976127.
[32]
Qin X, Song Y.Bioinformatics analysis identifies the estrogen receptor 1 (ESR1) Gene and hsa-miR-26a-5p as potential prognostic biomarkers in patients with intrahepatic cholangiocarcinoma[J].Med Sci Monit, 2020, 26: e921815.
[33]
Carotenuto P, Hedayat S, Fassan M, et al.Modulation of biliary cancer chemo-resistance through microRNA-mediated rewiring of the expansion of CD133+ cells[J].Hepatology, 2020, 72(3): 982-996.
[34]
Wu J, Yang B, Zhang Y, et al.miR-424-5p represses the metastasis and invasion of intrahepatic cholangiocarcinoma by targeting ARK5[J].Int J Biol Sci, 2019, 15(8): 1591-1599.
[1] 卢晓云, 黄勇, 王继伟, 李建国, 谢铭. 直肠癌预防性造口还纳时机研究进展[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(02): 216-219.
[2] 吉林霞, 范小春, 梁琴. 胃癌常见术后并发症类型及危险因素研究进展[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(02): 220-223.
[3] 杨培容, 潘刚, 周春霞. 胰腺癌术后胰瘘的危险因素及治疗进展[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(02): 228-230.
[4] 苏明, 唐丹萍, 王萍, 何谦. 乳腺癌改良根治术后即刻乳房重建的方法选择研究进展[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(02): 231-234.
[5] 吉玉洁, 尚培中, 王金, 张伟, 聂阿娜, 胡玮, 张丹, 王晓梅. 原位保留瘘口处肠段回肠盲肠Overlap吻合预防回肠阴道瘘复发一例报道[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(02): 235-236.
[6] 肖建, 肖天保, 陈江, 杨桃, 何峰, 保甜甜, 曹一波, 杨琴, 赵颖. 吲哚菁绿成像技术在保留左结肠动脉的直肠癌根治术中的应用价值[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(02): 134-137.
[7] 左从奎, 毕迎春, 姚琼. 不同IMV 结扎水平的直肠癌全直肠系膜切除术临床效果对比研究[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(02): 138-141.
[8] 金芳, 徐东飞, 尚培中, 张伟, 葛艳丽, 李晓英, 苗建军, 郭伟林. 腹腔镜直肠癌Dixon手术选择性应用超声刀和电钩的效果评价[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(02): 142-145.
[9] 周丽君, 王露, 林巧. 腹腔镜与开腹直肠癌切除术治疗中低位直肠癌的疗效及并发症对比[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(02): 146-148.
[10] 何可可, 顾海扬, 肖姝, 韦琪, 李鑫玉. 腹腔镜保留回盲部右半结肠切除术治疗右半结肠癌的临床效果研究[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(02): 149-152.
[11] 陈宝鹤, 张文卓, 王隽. 头尾侧联合入路腹腔镜右半结肠癌根治术的近中期临床观察[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(02): 153-156.
[12] 韦洋, 赵远权, 王小波, 黄海, 陈洁. BCLC 0/A期肝细胞癌患者术后辅助治疗后早期复发风险分析及预测模型建立[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(02): 157-161.
[13] 艾世超, 孙艺文, 宋鹏, 沈晓菲, 刘颂, 孙锋, 陆晓峰, 王萌, 管文贤. 静脉注射吲哚菁绿导航胃癌根治术的单臂开放前瞻性研究[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(02): 166-169.
[14] 李峥, 马晋峰. 基于炎症反应评分系统构建预测根治性术后食管胃结合部腺癌患者预后的列线图模型[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(02): 170-175.
[15] 李贞贞, 王宏刚, 崔丽丽, 缪月琴, 刘万璐. 改良管状胃—食管吻合术在腹腔镜近端胃切除消化道重建中的安全性及抗反流效果研究[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(02): 176-179.
阅读次数
全文


摘要